| Peter C Gay, MD | |
|
200 1st St Sw, Rochester, MN 55905-0001 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Peter C Gay |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 43 Years |
| Location | 200 1st St Sw, Rochester, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891765228 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 26947 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Hospital Rochester | Rochester, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic | 6507778255 | 4232 |
| Mayo Clinic Health System-lake City | 1951213487 | 49 |
| Mayo Clinic Health System-southeast Minnesota Region | 4385556703 | 573 |
News Archive
Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.
The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.
The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform.
Researchers utilizing computed tomography (CT) scans have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli (PE), according to a study to be published online Oct. 14, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.
An analysis of a patient's deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.
› Verified 1 days ago
| Entity Name | Mayo Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922074434 PECOS PAC ID: 6507778255 Enrollment ID: O20031103000285 |
News Archive
Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.
The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.
The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform.
Researchers utilizing computed tomography (CT) scans have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli (PE), according to a study to be published online Oct. 14, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.
An analysis of a patient's deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-lake City |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164463659 PECOS PAC ID: 1951213487 Enrollment ID: O20031104000095 |
News Archive
Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.
The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.
The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform.
Researchers utilizing computed tomography (CT) scans have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli (PE), according to a study to be published online Oct. 14, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.
An analysis of a patient's deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891701637 PECOS PAC ID: 4385556703 Enrollment ID: O20031104000408 |
News Archive
Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.
The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.
The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform.
Researchers utilizing computed tomography (CT) scans have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli (PE), according to a study to be published online Oct. 14, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.
An analysis of a patient's deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545422 PECOS PAC ID: 4688585771 Enrollment ID: O20031110000134 |
News Archive
Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.
The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.
The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform.
Researchers utilizing computed tomography (CT) scans have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli (PE), according to a study to be published online Oct. 14, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.
An analysis of a patient's deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-fairmont |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366410862 PECOS PAC ID: 4981694981 Enrollment ID: O20040719000142 |
News Archive
Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.
The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.
The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform.
Researchers utilizing computed tomography (CT) scans have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli (PE), according to a study to be published online Oct. 14, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.
An analysis of a patient's deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System St James |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023177730 PECOS PAC ID: 9537170352 Enrollment ID: O20060509000021 |
News Archive
Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.
The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.
The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform.
Researchers utilizing computed tomography (CT) scans have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli (PE), according to a study to be published online Oct. 14, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.
An analysis of a patient's deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-lake City |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1538113022 PECOS PAC ID: 1951213487 Enrollment ID: O20070711000490 |
News Archive
Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.
The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.
The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform.
Researchers utilizing computed tomography (CT) scans have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli (PE), according to a study to be published online Oct. 14, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.
An analysis of a patient's deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System St James |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1639198732 PECOS PAC ID: 9537170352 Enrollment ID: O20080108000344 |
News Archive
Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.
The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.
The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform.
Researchers utilizing computed tomography (CT) scans have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli (PE), according to a study to be published online Oct. 14, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.
An analysis of a patient's deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1740256668 PECOS PAC ID: 4688585771 Enrollment ID: O20171011003933 |
News Archive
Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.
The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.
The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform.
Researchers utilizing computed tomography (CT) scans have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli (PE), according to a study to be published online Oct. 14, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.
An analysis of a patient's deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1124035282 PECOS PAC ID: 4688585771 Enrollment ID: O20171011003939 |
News Archive
Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.
The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.
The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform.
Researchers utilizing computed tomography (CT) scans have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli (PE), according to a study to be published online Oct. 14, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.
An analysis of a patient's deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1063435410 PECOS PAC ID: 4385556703 Enrollment ID: O20171011003946 |
News Archive
Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.
The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.
The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform.
Researchers utilizing computed tomography (CT) scans have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli (PE), according to a study to be published online Oct. 14, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.
An analysis of a patient's deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peter C Gay, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Peter C Gay, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 |
News Archive
Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.
The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.
The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform.
Researchers utilizing computed tomography (CT) scans have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli (PE), according to a study to be published online Oct. 14, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.
An analysis of a patient's deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.
› Verified 1 days ago
Emily Leasure, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Jorge A Velosa, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Michael Ruediger Mueller, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Mr. Karun Singh Badwal, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Michal Reid, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Katherine Desprez Wick, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Dr. Allison Bock, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |